A Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure

PHASE2CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

February 28, 2015

Study Completion Date

February 29, 2016

Conditions
Ischemic CardiomyopathyNon-ischemic CardiomyopathyHeart FailureCardiomyopathies
Interventions
GENETIC

AAV1/SERCA2a (MYDICAR)

Single intracoronary infusion 1 x 10\^13 DNase Resistant Particles (DRP) MYDICAR

GENETIC

Placebo

Single intracoronary infusion

Trial Locations (54)

Unknown

Birmingham

La Jolla

Long Beach

San Diego

Sylmar

Newark

Jacksonville

Miami

Augusta

Iowa City

Alexandria

Boston

Kansas City

St Louis

New York

The Bronx

Winston-Salem

Columbus

Oklahoma City

Philadelphia

Charleston

Rapid City

Germantown

Tullahoma

Houston

San Antonio

Salt Lake City

Tacoma

Waukesha

Aalst

Leuven

Aalborg

Coppenhagen

Hvidovre

Bad Nauheim

Berlin

Cologne

Dresden

München

Budapest

Debrecen

Ashkelon

Holon

Jerusalem

Rehovot

Groningen

Gdansk

Wroclaw

Zabrze

Malmo

Örebrö

Stockholm

Glasgow

London

Sponsors
All Listed Sponsors
lead

Celladon Corporation

INDUSTRY